Literature DB >> 26381776

Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment.

Emilio Bombardieri1, L Evangelista2, G L Ceresoli3, F Boccardo4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26381776     DOI： 10.1007/s00259-015-3189-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  17 in total

1.  Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Authors:  Jorge A Carrasquillo; Joseph A O'Donoghue; Neeta Pandit-Taskar; John L Humm; Dana E Rathkopf; Susan F Slovin; Matthew J Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M Larson; Howard I Scher; Michael J Morris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

Review 2.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

3.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

Authors:  Gjermund Henriksen; Knut Breistøl; Øyvind S Bruland; Øystein Fodstad; Roy H Larsen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

4.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

Authors:  Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

5.  Plasma concentration and excretion of calcium-47, strontium-85, barium-133 and radium-223 following successive intravenous doses to a healthy man.

Authors:  G E Harrison; T E Carr; A Sutton; J Rundo
Journal:  Nature       Date:  1966-01-29       Impact factor: 49.962

Review 6.  Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.

Authors:  Julie N Graff; Tomasz M Beer
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

Review 7.  Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.

Authors:  Aurelius Omlin; Carmel Pezaro; Silke Gillessen Sommer
Journal:  Ther Adv Urol       Date:  2014-02

Review 8.  Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.

Authors:  Riccardo Valdagni; Hendrik Van Poppel; Michael Aitchison; Peter Albers; Dominik Berthold; Alberto Bossi; Maurizio Brausi; Louis Denis; Lawrence Drudge-Coates; Maria De Santis; Günther Feick; Chris Harrison; Karin Haustermans; Donal Hollywood; Morton Hoyer; Henk Hummel; Malcolm Mason; Vincenzo Mirone; Stefan C Müller; Chris Parker; Mahasti Saghatchian; Cora N Sternberg; Bertrand Tombal; Erik van Muilekom; Maggie Watson; Simone Wesselmann; Thomas Wiegel; Tiziana Magnani; Alberto Costa
Journal:  Crit Rev Oncol Hematol       Date:  2015-06-05       Impact factor: 6.312

9.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 10.  Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Authors:  Ethan Basch; D Andrew Loblaw; Thomas K Oliver; Michael Carducci; Ronald C Chen; James N Frame; Kristina Garrels; Sebastien Hotte; Michael W Kattan; Derek Raghavan; Fred Saad; Mary-Ellen Taplin; Cindy Walker-Dilks; James Williams; Eric Winquist; Charles L Bennett; Ted Wootton; R Bryan Rumble; Stacie B Dusetzina; Katherine S Virgo
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.